JP2020503356A5 - - Google Patents

Info

Publication number

JP2020503356A5

JP2020503356A5 JP2019536215A JP2019536215A JP2020503356A5 JP 2020503356 A5 JP2020503356 A5 JP 2020503356A5 JP 2019536215 A JP2019536215 A JP 2019536215A JP 2019536215 A JP2019536215 A JP 2019536215A JP 2020503356 A5 JP2020503356 A5 JP 2020503356A5

Authority

JP

Japan

Prior art keywords

nitroxyl

pharmaceutical composition

hours

composition according

donating compound

Prior art date

2018-01-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 42
• ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims 40
• 239000008194 pharmaceutical composition Substances 0.000 claims 38
• 238000000034 method Methods 0.000 claims 17
• 229920000742 Cotton Polymers 0.000 claims 15
• 229920000858 Cyclodextrin Polymers 0.000 claims 15
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 13
• 208000024172 Cardiovascular disease Diseases 0.000 claims 12
• 238000002560 therapeutic procedure Methods 0.000 claims 8
• KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims 7
• 239000000203 mixture Substances 0.000 claims 6
• NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical class OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 4
• 230000002411 adverse Effects 0.000 claims 4
• 229960004853 betadex Drugs 0.000 claims 4
• 238000004448 titration Methods 0.000 claims 4
• 206010007556 Cardiac failure acute Diseases 0.000 claims 2
• 239000001116 FEMA 4028 Substances 0.000 claims 2
• 206010019280 Heart failures Diseases 0.000 claims 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
• 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical group [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims 2
• 239000003381 stabilizer Substances 0.000 claims 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical group [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
• 238000001990 intravenous administration Methods 0.000 claims 1
• 235000011056 potassium acetate Nutrition 0.000 claims 1
• 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
• 235000011009 potassium phosphates Nutrition 0.000 claims 1
• 230000001568 sexual effect Effects 0.000 claims 1
• 0 CS(c1cccc(*)c1)(=O)=O Chemical compound CS(c1cccc(*)c1)(=O)=O 0.000 description 2